Although not covered much in the western media, Chinese companies have, owing to a situation of time, being leading the way in the establishment of a covid-19 vaccine, with several companies having already made it into stage two trials. The independent medical journal, The Lancet, has now reviewed and published the results of some of the phase one trials in China and now found them to be to be safe, well-tolerated, and able to generate an immune response against SARS-COV-2 in humans.
China has approved three COVID-19 vaccine candidates for clinical trials, with the recombinant adenovirus vector-based vaccine (Ad5-nCoV) listed as the world’s first vaccine to go into phase two by the World Health Organization. This type of vaccine is able to act as a natural infection and is especially good at teaching the immune system how to fight the virus.
The complete study may be found here.
